تعليقIndividuals prescribed the longer treatment regimen should be monitored to assess regimen effectiveness and safety, taking into account resistance patterns and challenging clinical conditions, while using less active and more toxic medicines. The WHO framework for aDSM needs to be applied to patients on any MDR-TB regimen, to ensure appropriate action and an acceptable level of monitoring for and prompt response to adverse events – alongside monitoring for treatment outcomes, including early monitoring for treatment failure.
